Cisplatin and gemcitabine with either vinorelbine or paclitaxel in the treatment of carcinomas of unknown primary site: Results of an Italian multicenter, randomized, phase II study

Cancer

Volumn 107, Issue 12, 2006, Pages 2898-2905

  Palmeri, Sergio ^a   Lorusso, Vito ^b   Palmeri, Laura ^a   Vaglica, Marina ^a   Porta, Camillo ^c   Nortilli, Rolando ^d   Ferraú, Francesco ^e   Comella, Giuseppe ^f   Massidda, Bruno ^g   Danova, Marco ^c  

^a UNIVERSITY OF PALERMO   (Italy)

^b NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

^c Division of Medical Oncology   (Italy)

^d UNIVERSITY OF VERONA   (Italy)

^e Taormina Hospital   (Italy)

^f NATIONAL CANCER INSTITUTE   (Italy)

^g UNIVERSITY OF CAGLIARI   (Italy)

Author keywords

Carcinoma; Chemotherapy; Cisplatin; Gemcitabine; Paclitaxel; Unknown primary; Vinorelbine

Indexed keywords

ANTIEMETIC AGENT; ANTIHISTAMINIC AGENT; CARBOPLATIN; CISPLATIN; GEMCITABINE; IRINOTECAN; NAVELBINE; PACLITAXEL; STEROID; TAXANE DERIVATIVE;

ADD ON THERAPY; ADULT; AGED; ANEMIA; ARTICLE; ASTHENIA; BONE CANCER; BONE METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CARCINOMA; CARDIOTOXICITY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; FEMALE; HUMAN; ITALY; KAPLAN MEIER METHOD; LIVER CANCER; LIVER METASTASIS; LIVER TOXICITY; LUNG CANCER; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; PANCREAS CANCER; PHASE 2 CLINICAL TRIAL; PLEURA CANCER; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; SKIN CANCER; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA; CISPLATIN; DEOXYCYTIDINE; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; ITALY; MALE; MIDDLE AGED; NEOPLASMS, UNKNOWN PRIMARY; PACLITAXEL; VINBLASTINE;

EID: 33845584630     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.22379     Document Type: Article

References (40)

1. Pavlidis N, Fizazi K. Cancer of unknown primary (CUP). Crit Rev Oncol Hematol. 2005;54:243-250.
2. Greco FA, Hainsworth JD. Tumors of unknown origin. CA Cancer J Clin. 1992;42:96-115.
3. Culine S, Kramar A, Saghatchian M, et al. Development and validation of a prognostic model to predict the length of survival in patients with carcinomas of an unknown primary site. J Clin Oncol. 2002;20:4679-4683.
4. Pavlidis N, Kosmidis P, Skarlos D, et al. Subsets of tumors responsive to cisplatin or carboplatin combinations in patients with carcinoma of unknown primary site. A Hellenic Cooperative Oncology Group Study. Ann Oncol. 1992;3:631-634.
5. Bugat R, Bataillard A, Lesimple T, et al. Summary of the standards, options and recommendations for the management of patients with carcinoma of unknown primary site. Br J Cancer. 2003;89(suppl 1):S59-S66.
6. Miller AB, Hoogstraten B, Staquet M, et al. Reporting results of cancer treatment. Cancer. 1981;47:207-214.
7. Trotti A, Colevas AD, Setser A, et al. CTCAE version 3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol. 2003;13:176-181.
8. Simon R. Optimal two-stage designs for Phase II clinical trials in oncology. Control Clin Trials. 1989;10:1-10.
9. Kaplan EL, Meier P. Non parametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
10. Hess KR, Abbruzzese MC, Lenzi R, Raber MN, Abbruzzese JL. Classification and regression tree analysis of 1000 consecutive patients with unknown primary carcinoma. Clin Cancer Res. 1999;5:3403-3410.
11. Goldberg RM, Smith FP, Ueno W, et al. 5-Fluorouracil, Adriamycin and mitomycin in the treatment of adenocarcinoma of unknown primary. J Clin Oncol. 1986;4:395-399.
12. Treat J, Falchuk SC, Tremblay C, et al. Phase II trial of methotrexate-FAM (m-FAM) in adenocarcinoma of unknown primary. Eur J Clin Oncol. 1989;25:1053-1059.
13. Woods RL, Fox RM, Tattersall MHN, et al. Metastatic adenocarcinomas of unknown primary: a randomized study of two combination-chemotherapy regimens. N Engl J Med. 1980;303:87-89.
14. Milliken ST, Tattersall MHN, Woods RL, et al. Metastatic adenocarcinoma of unknown primary site: a randomized study of two combination chemotherapy regimens. Eur J Cancer Clin Oncol. 1987;23:1645-1650.
15. Eagan RT, Therneau TM, Rubin J, Long HJ, Schutt AJ. Lack of value for cisplatin added to mitomycin-doxorubicin combination chemotherapy for carcinoma of unknown primary site. A randomized trial. Am J Clin Oncol. 1987;10:82-85.
16. Anderson H, Thatcher N, Randin E, et al. VAC (vincristine, Adriamycin and cyclophosphamide) chemotherapy for metastatic carcinoma from an unknown primary site. Eur J Cancer Clin Oncol. 1983;19:49-52.
17. De Campos ES, Menace LP, Radford J, et al. Metastatic carcinoma of uncertain primary site: a retrospective review of 57 patients treated with vincristine, doxorubicin, cyclophosphamide (VAC) or VAC alternating with cisplatin and etoposide (VAC/EP). Cancer. 1994;73:470-475.
18. Raber MN, Faintuch J, Abbruzzese JL, et al. Continuous infusion 5-fluorouracil, etoposide and cis-diamminedichloroplatinum in patients with metastatic carcinoma of unknown primary origin. Ann Oncol. 1991;2:519-520.
19. Gill I, Guaglianone P, Grunberg SM, et al. High dose intensity of cisplatin and etoposide in adenocarcinoma of unknown primary. Anticancer Res. 1991;11:1231-1235.
20. Falkson CI, Cohen GL. Mitomycin and cisplatin versus mitomycin alone as therapy for carcinoma of unknown primary origin. Oncology. 1998;55:116-121.
21. Briasoulis E, Kalofonos H, Bafaloukos H, et al. Carboplatin plus paclitaxel in unknown primary carcinoma: a Phase II Hellenic Cooperative Oncology Group study. J Clin Oncol. 2000;18:3101-3107.
22. Greco FA, Burris HA, Erland JB, et al. Carcinoma of unknown primary site. Long-term follow up after treatment with paclitaxel, carboplatin and etoposide. Cancer. 2000;89:2655-2660.
23. Greco FA, Erland JB, Morrissey LH, et al. Carcinoma of unknown primary site: Phase II trials with docetaxel plus cisplatin or carboplatin. Ann Oncol. 2000;11:211-215.
24. Greco FA, Burris HA, Litchy S, et al. Gemcitabine, carboplatin, and paclitaxel for patients with carcinoma of unknown primary site: a Minnie Pearl Cancer Research Network study. J Clin Oncol. 2002;20:1651-1656.
25. Greco FA, Rodriguez GI, Shaffer DW, et al. Carcinoma of unknown primary site: sequential treatment with paclitaxel/ carboplatin/etoposide and gemcitabine/irinotecan: a Minnie Pearl Cancer Research Network Phase II trial. Oncologist. 2004;9:644-652.
26. Greco FA, Litchy S, Dannaher C, et al. Carcinoma of unknown primary site with unfavorable characteristics: survival of 396 patients after treatment with five consecutive phase II trials by the Minnie Pearl Cancer Research Network. Proc Am Soc Clin Oncol. 2004;22:14S. Abstract 4186.
27. Hainsworth JD, Burris HA, Calvert SW, et al. Gemcitabine in the second-line therapy of patients with carcinoma of unknown primary site: a Phase II trial of the Minnie Pearl Cancer Research Network. Cancer Invest. 2001;19:335-339.
28. Hainsworth JD, Spigel DR, Raefsky EL, et al. Combination chemotherapy of gemcitabine and irinotecan in patients with previously treated carcinoma of an unknown primary site: a Minnie Pearl Cancer Research Network Phase II trial. Cancer. 2005;104:1992-1997.
29. Balana C, Manzano J-L, Moreno I, et al. A Phase II study of cisplatin, etoposide and gemcitabine in an unfavourable group of patients with carcinoma of unknown primary site. Ann Oncol. 2003;14:1425-1429.
30. Culine S, Lortholary A, Voigt JJ, et al. Cisplatin in combination with either gemcitabine or irinotecan in carcinomas of unknown primary site: results of a randomized Phase II study. Trial for the French Study Group on Carcinomas of Unknown Primary (GEFCAPI 01). J Clin Oncol. 2003;21:3479-3482.
31. Piga A, Nortilli R, Cetto GL, et al. Carboplatin, doxorubicin and etoposide in the treatment of tumours of unknown primary site. Br J Cancer. 2004;90:1898-1904.
32. Huebner G, Steinbach S, Kohne CH, et al. Paclitaxel (P)/carboplatin (C) versus gemcitabine (G)/vinorelbine (V) in patients with adeno- or undifferentiated carcinoma of unknown primary (CUP) - a randomized prospective Phase II trial. Proc Am Soc Clin Oncol. 2005;23(16S):330s. Abstract 4089.
33. Le Chevalier T, Cvitkovic E, Caille P, et al. Early metastatic cancer of unknown primary origin at presentation. A clinical study of 302 consecutive autopsied patients. Arch Intern Med. 1988;148:2035-2039.
34. Dowell JE, Garrett AM, Shyr Y, Johnson DH, Hande KR. A randomized Phase II trial in patients with carcinoma of unknown primary site. Cancer. 2001;91:592-597.
35. Pouessel D, Culine S, Becht S, et al. Gemcitabine and docetaxel as front-line chemotherapy in patients with carcinoma of an unknown primary site. Cancer. 2003;100:1257-1261.
36. Park YH, Ryoo BY, Choi SJ, Yang SH, Kim HT. A Phase II study of paclitaxel plus cisplatin chemotherapy in an unfavourable group of patients with cancer of unknown primary site. Jpn J Clin Oncol. 2004;34:681-685.
37. El-Rayes BF, Shields AF, Zalupski M, et al. A Phase II study of carboplatin and paclitaxel in adenocarcinoma of unknown primary. Am J Clin Oncol. 2005;28:152-156.
38. Schneider BJ, Muler J, Philip P, et al. A Phase II trial of carboplatin, gemcitabine and capecitabine in patients with carcinoma of unknown primary site (CUP). Proc Am Soc Clin Oncol. 2005;23(16S):330s. Abstract 4090.
39. Pittman KB, Olver IN, Karapetis CS, et al. Multicenter Phase II study of gemcitabine and carboplatin combination therapy for patients with metastatic carcinoma of unknown primary site: final results. Proc Am Soc Clin Oncol. 2005;23(16S):764s. Abstract 8142.
40. Varadhachary GR, Blais JC, Raber MN, Lenzi P, Hoff PM, Abbruzzese JL. Phase II study to evaluate the efficacy and toxicity of oxaliplatin in combination with gemcitabine (GEMOX) in cancer of unknown primary (CUP). Proc Am Soc Clin Oncol. 2005;23(16S):342s. Abstract 4140.